Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05542199
Other study ID # 2273
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 13, 2022
Est. completion date November 1, 2023

Study information

Verified date September 2022
Source Tufts University
Contact Susan B. Roberts, Ph.D.
Phone 617-556-3237
Email susan.roberts@tufts.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the trial is to determine the feasibility of implementing a specific nutrition regimen used alone or in combination with a behavioral weight loss (WL) intervention on cognition and cerebral blood flow in older adults at risk of cognitive decline.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date November 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 85 Years
Eligibility Major inclusion criteria: 1. Adult women and men aged 55-85 years. 2. BMI of 27.0-39.9 kg/m2 at screening (higher BMIs not included at this time to facilitate program adherence); 3. Scores of 34 or greater on the Modified Telephone Interview for Cognitive Status (TICS-M) at screening (85). The purpose of this screen is to ensure that participants can give consent and adhere to the study requirements, including the outcomes testing. 4. Willing to be randomized and participate in all study components, including consuming the foods and supplements, participating in the WL intervention or control meetings, being available for outcome assessments, using the provided home Wi-Fi scale and activity monitor daily, and completing questionnaires, as well as providing the login information for scales and activity monitor so investigators can download the data. 5. Satisfactory screening review of health history questionnaire by nursing staff for relevant factors including no evidence of exclusions listed below. This will include verbal confirmation of completing a course of vaccination against COVID-19 (two doses plus one booster prior to screening visit). The reason for this study component is that live group meetings are planned with other participants, and this will reduce participant risk. 6. Has access to computer or smartphone with Wi-Fi and possesses a freezer at home with space for supplement storage. 7. Rates representative food with characteristics of the MCNS and control foods at least 4 on a 5-point scale of liking at screening, and reports that they are willing to consume the food daily. 8. Average energy intake in 3 24-h dietary recalls is within physiological (i.e., plausible) range. Major exclusion criteria: 1. >25% percentile in most recent data for US adult population intake for reported DHA/EPA in screening questionnaire for rich food sources, which is equivalent to 2 or more servings of fatty fish/month (86, 87). 2. Regularly taking a multivitamin, cacao/cocoa supplement, choline supplement, DHA/EPA supplement, or any supplement advertised for brain health or cognitive function (>1/week). Washout period of 2 months accepted. 3. Does not like, or alternatively reports eating >1 serving per week of >60% chocolate or cocoa. 4. Severe cardiovascular disease including stroke, heart failure, coronary bypass and valve replacement, coronary bypass or any surgical procedures or signs and symptoms of current severe cardiovascular disease. 5. History of neurological brain disease, including stroke, seizure disorders, traumatic brain injury (moderate to severe); including prior diagnosis of a neurodegenerative disease including AD and Parkinson's disease, frontotemporal dementia. Moderate traumatic brain injury is defined by an injury with loss of consciousness. 6. Major psychiatric disorder history (schizophrenia, bipolar affective disorder, intractable depression). 7. Inadequately controlled hypertension at the discretion of study MD or RN 8. Diabetes Type 1 & Type 2 or use of any pharmacological treatment for diabetes or HbA1c >6.5 at screening. 9. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol. This includes the lost of smell or taste. 10. History of stomach or bowel resection (other than appendectomy), gastric bypass, or other bariatric weight loss procedure 11. GI diseases, conditions or meds known to influence GI absorption including active peptic ulcer disease or inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), Celiac disease, Cystic Fibrosis, malabsorption disorders, gallbladder disease, acute or chronic pancreatitis or Pancreatic insufficiency 12. Chronic kidney disease or history of kidney stones 13. History of diagnosed eating disorder anorexia, bulimia or binge-eating 14. Active treatment for cancer (except non-melanoma skin cancer) of any type in = 3 year. 15. Thyroid disease or other significant endocrine disorder 16. Uncontrolled hypercholesterolemia. 17. History of acute or chronic pancreatitis or gall bladder disease. 18. Metabolic disorders or conditions that interfere with nutrient absorption (such as Phenylketonuria, Maple Syrup Urine Disease, glucose-galactose malabsorption, ornithine transcarbamylase deficiency or hypophosphatemic rickets.) 19. Dose adjustment to statin or antihypertensive medication within the past 3 months 20. Screening lab results outside the normal parameters that may interfere with study outcomes at the discretion of study MD 21. Inadequate venous access or history of a bilateral mastectomy with nodal dissection 22. Recent history of inflammatory diseases (for example: rheumatoid arthritis, lupus) 23. Active WL, or weight change > 4 kg in past 6 months. 24. Consuming a restrictive diet (e.g. gluten-free, vegan, Paleolithic diet). 25. Self-reported allergy to any ingredient in the provided intervention foods. 26. Self-reported severe allergy to adhesives. 27. Unwilling to use a mobile phone or computer with videoconference software to participate in intervention group meetings. Unwilling to eat on camera. 28. Reports of consumption of > 2 alcoholic drinks per day on average or >14/week (168oz beer/56oz wine/14oz hard liquor.) 29. Reports of consumption of > 2 cups of green or black tea per day on average. 30. Reports of use of recreational and/or illegal drugs. 31. Regular smoking or vaping tobacco or marijuana including the use of edibles within the last 6 months (greater than once a week) 32. Non-English speakers. 33. No social security number (required for stipend payment).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Multicomponent nutrition supplement (MCNS)
Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
Behavioral:
Behavioral weight loss program
Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.

Locations

Country Name City State
United States Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University Boston Massachusetts

Sponsors (4)

Lead Sponsor Collaborator
Tufts University Massachusetts General Hospital, University of Florida, University of New Hampshire

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Weight loss Change in body weight from baseline Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Primary Cognitive function Change in age-sensitive cognitive composite z-score from baseline, based on well-established standardized scores on 5 neuropsychological tests (Controlled Oral; Word Association Test, Digit Symbol Substitution Test; Stroop Interference Test; Trails Making Tests A and B) Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Secondary Microvascular cerebral blood flow in fasting state Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fasting state Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Secondary Microvascular cerebral blood flow in fed state Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fed state Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Secondary Macrovascular cerebral blood flow velocity in fasting state Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fasting state Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Secondary Macrovascular cerebral blood flow velocity in fed state Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fed state Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2